Why Moderna Is Less Risky Than You Think
Biotech investing is not for the weak-hearted. While the clinical and regulatory success of a drug can mean huge gains, any failure in the development and commercialization process can literally decimate a biotech investor's portfolio.
Many investors consider Moderna (NASDAQ: MRNA) to be one such risky biotechnology company, with fortunes largely dependent on the success or failure of its experimental COVID-19 vaccine, mRNA-1273. But although Moderna may be riskier than other prominent COVID-19 vaccine players such as Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN), that doesn't mean it's purely a speculative play. mRNA-1273 is definitely the biggest short-term growth driver for the company -- but Moderna also has much more to offer in the field of mRNA therapeutics.
Image Source: Getty Images.
Source Fool.com
